A 50-year-old patient walked into a Dubai clinic last quarter with a problem he could not see in the mirror. His BMI was 24.8, technically in the normal range. He had run two half-marathons in the past year. He thought he was fine. His annual blood work said otherwise. Fasting glucose was 108 mg/dL. HbA1c was 6.0, sitting on the edge of pre-diabetes. Triglycerides were elevated, HDL was suppressed, and his physician had ordered a fasted abdominal ultrasound that showed a noticeable layer of visceral fat wrapped around the liver and the small intestine.
On paper he was a healthy weight. Underneath the skin he was carrying the metabolic profile of someone two clinical categories higher. This is the patient phenotype clinicians sometimes call thin outside, fat inside. It is exactly the patient population for whom tesamorelin was originally developed, and it is one of the more common metabolic presentations in adult patients across the GCC.
Tesamorelin is one of the most clinically credible peptides in the longevity conversation. It has FDA approval, completed phase III trials, and a real evidence base. It also sits in an awkward space: approved for one specific indication, used off-label for a much broader one. This article walks through what tesamorelin actually does, what the evidence shows, where the off-label conversation is defensible, and why visceral fat is a particularly UAE problem.
Visceral fat is a different drug
Adipose tissue is not one thing. Subcutaneous fat is the layer you can pinch above the waistband of a pair of trousers. Visceral fat sits deeper, packed around the liver, pancreas, intestines, and mesentery. The two tissues look similar under a microscope, but they behave like entirely different organs.
Visceral adipose tissue is endocrine-active. It releases inflammatory cytokines (TNF-alpha, IL-6), free fatty acids, and adipokines that drive insulin resistance and systemic inflammation. Subcutaneous fat is comparatively quiet. The result is that two patients with identical BMIs and identical waist sizes can have entirely different cardiovascular and metabolic risk profiles depending on where the fat is distributed.
The evidence on this is now overwhelming. A landmark review in Circulation established that visceral adiposity is independently associated with cardiovascular events, type 2 diabetes, and all-cause mortality, even at normal BMI [Despres, Circulation, 2012]. Subsequent imaging cohort studies have confirmed the relationship at scale. Visceral fat is not a cosmetic problem. It is a metabolic and cardiovascular risk factor that is sometimes invisible at the level of the bathroom scale.
Why this matters in the GCC
The UAE has one of the highest prevalences of type 2 diabetes in the world. The International Diabetes Federation Atlas places adult diabetes prevalence in the UAE in the 16 to 19 percent range, and the broader GCC region tracks similarly [International Diabetes Federation Atlas]. Pre-diabetes is more common still. The drivers are well documented: a regional dietary transition over the past three decades, a climate that pushes daily life indoors for half the year, and a lifestyle in which sedentarism is structurally easier than activity.
Layered on top of that is body composition. The South Asian and Middle Eastern phenotype, well represented in the UAE expat and national population, accumulates visceral fat at lower BMI thresholds than European reference data predicts. The clinical literature now recommends adjusted BMI cut-offs for South Asian populations specifically because the metabolic risk per unit of fat mass is higher. A patient at BMI 23 in this region can carry the visceral fat burden of someone at BMI 28 in northern Europe. This is why a normal BMI is no longer a reliable filter for metabolic risk in UAE clinical practice [GCC Health Council reports].
The downstream consequence is that non-alcoholic fatty liver disease (NAFLD) prevalence in the region is high and rising. Liver fat fraction tracks with visceral fat. Patients who present at clinic with a normal BMI, an expanding waistline, and incidentally elevated liver enzymes are now a routine line item in UAE primary care. NAFLD is the silent partner of visceral adiposity. The two run together, and they progress together.
What tesamorelin actually is
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). Native GHRH is a 44-amino-acid peptide produced in the hypothalamus. Tesamorelin is a stabilized version of the same molecule, engineered to resist enzymatic degradation and last long enough in circulation to be useful as an injected drug. It is sold under the trade name Egrifta.
The mechanism is upstream. Tesamorelin binds to GHRH receptors on the anterior pituitary and stimulates the pituitary to release the patient's own endogenous growth hormone in pulses, the way a healthy GHRH signal would. This is different from injecting recombinant human growth hormone directly. The pituitary is being asked to do its normal job, not bypassed. The result is a measured rise in serum IGF-1 (the downstream growth hormone effector) without the supraphysiologic peaks that come with injected hGH.
Tesamorelin received FDA approval in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [FDA prescribing information, Egrifta]. The approval was based on phase III trials showing meaningful and consistent reduction in visceral adipose tissue over 26 weeks of daily 2 mg subcutaneous injection [Falutz et al., NEJM, 2010]. Across two pooled phase III studies, visceral adipose tissue decreased by approximately 15 to 18 percent in the treatment arm versus essentially no change in the placebo arm. The effect was reproducible, the safety profile was acceptable, and the on-label evidence was strong enough that the drug has been on the international pharmaceutical formulary for more than fifteen years.
The off-label conversation
The reason tesamorelin shows up in longevity clinics today is that the visceral-fat reduction effect is not specific to HIV patients. The mechanism is GHRH-receptor signaling at the pituitary, which is the same pathway in everyone. So the natural clinical question became: does tesamorelin reduce visceral fat in metabolically-at-risk patients without HIV?
The off-label evidence is smaller but it is real. Stanley and colleagues ran a randomized placebo-controlled trial of tesamorelin in non-HIV patients with abdominal adiposity and showed reductions in visceral fat broadly comparable to the HIV cohort, with similar safety [Stanley et al., JAMA, 2014]. The effect was reproducible. Subsequent investigator-led work has extended this into specific metabolic sub-populations, most notably patients with NAFLD.
The NAFLD work matters specifically for the UAE. Stanley and colleagues published a randomized trial in Hepatology demonstrating that tesamorelin reduced liver fat fraction (measured by MR spectroscopy) in patients with NAFLD over 12 months, alongside the expected reduction in visceral adipose tissue [Stanley et al., Hepatology, 2019]. The effect on liver fat was not subtle. In a region where NAFLD prevalence is high and rising, this is a clinically interesting finding.
Off-label is not a synonym for unsupported. Most clinicians who prescribe tesamorelin off-label do so under a specific frame: documented visceral adiposity, documented metabolic risk markers (elevated HbA1c, dyslipidemia, elevated liver enzymes, or imaging evidence of NAFLD), and a patient who has not improved on first-line lifestyle interventions over a meaningful period. That is a defensible clinical pathway. It is not the same as prescribing tesamorelin to a metabolically healthy patient who simply wants to be leaner.
What the protocol looks like
A properly run tesamorelin protocol in Dubai or Abu Dhabi has six predictable elements. The lab work is non-negotiable. Without baselines, there is no way to know whether the drug is doing what it is supposed to do.
- Baseline laboratory panel. Fasting glucose, HbA1c, comprehensive metabolic panel, lipid panel, liver function tests, and an IGF-1 level. The IGF-1 baseline is particularly important because tesamorelin's primary biomarker of effect is the IGF-1 response.
- Baseline body composition imaging. DEXA scan with visceral adipose tissue quantification is the gold standard. A fasted abdominal ultrasound for visceral fat thickness is the practical alternative when DEXA is not accessible. Without an objective baseline, the 12-week follow-up is just guesswork.
- Prescription written by a licensed physician. Standard dosing is 2 mg subcutaneous daily, typically administered in the evening because it leverages the body's natural overnight growth hormone pulse. The injection site rotates between the abdomen and the upper thigh.
- Dispensing through a licensed UAE pharmacy. Tesamorelin under its approved trade name (Egrifta) is on the regional pharmaceutical formulary and can be dispensed cleanly with the right authorizations. This is one of the more straightforward peptides to source legally in the UAE specifically because it is a fully approved drug.
- Supervised first dose. Subcutaneous self-injection is straightforward, but the first administration should be done with a registered nurse to walk through technique and rotation. DarDoc's home-visit model handles this directly.
- Follow-up labs and re-imaging at 12 weeks. IGF-1 to confirm the pituitary is responding. Fasting glucose and HbA1c to monitor the transient hyperglycemic effect. Repeat visceral fat quantification to confirm the drug is doing what it is supposed to do. Liver function tests if NAFLD was part of the baseline indication.
Speak to a DarDoc physician
Side effects and contraindications
The phase III safety profile is well characterized. The most common adverse events are injection-site reactions (redness, mild irritation), peripheral edema in the first weeks of therapy, and small transient elevations in fasting glucose. The glucose effect is consistent with the known counter-regulatory action of growth hormone on insulin sensitivity, which is why patients with poorly controlled diabetes are not good candidates without close monitoring [Falutz et al., NEJM, 2010].
Contraindications are explicit. Active malignancy is the central one. Tesamorelin raises IGF-1, and IGF-1 is a known mitogen with documented associations to certain cancer types, particularly breast, prostate, and colorectal [Pollak, Lancet Oncology, 2008]. Recent cancer history is a hard stop. Pregnancy and breastfeeding are absolute contraindications. Hypersensitivity to any component is a contraindication. Pituitary disease, recent pituitary surgery, or active hypothalamic injury are contraindications.
The IGF-1 conversation extends beyond cancer history. Patients with a strong family history of hormone-sensitive malignancy require a more careful risk-benefit conversation, even if they are themselves cancer-free. Patients with diabetic retinopathy require ophthalmologic clearance because growth hormone signaling can in principle aggravate proliferative retinal disease. None of this rules tesamorelin out. It rules out tesamorelin without a real consultation, which is the only way it should ever be prescribed in any case.
Who tesamorelin is for, and who it isn't
Tesamorelin is most defensible for the patient with documented visceral adiposity, documented metabolic risk markers, and a real history of attempting first-line interventions. The phenotype the article opened with (normal BMI, rising HbA1c, expanding waistline, evidence of fatty liver) sits cleanly in this category. So does the patient with established NAFLD who has not improved on dietary change alone.
- Patients with documented visceral adiposity (DEXA, ultrasound, or MRI confirmation) and elevated metabolic risk markers who have not improved on lifestyle interventions.
- Patients with NAFLD where liver fat reduction is a clinical goal and standard interventions have plateaued.
- HIV-positive patients with lipodystrophy. The original on-label population. Evidence is strongest here.
- Patients with a confirmed adult growth hormone deficiency or low-IGF-1 phenotype where a GHRH analog is preferable to direct hGH replacement.
Tesamorelin is not appropriate for patients seeking general weight loss. The drug acts on visceral fat specifically and does not produce meaningful reductions in subcutaneous fat or total body weight in most studies. A patient who wants to lose 10 kg of overall mass is asking for the wrong drug. GLP-1 receptor agonists, lifestyle intervention, or both are the right answer for that goal. Tesamorelin is also inappropriate for patients with active or recent malignancy, for patients who have not seriously attempted lifestyle change, for cosmetic indications, and for adolescents or young adults outside specific medical indications.
The bottom line
Tesamorelin is one of the cleaner stories in the peptide space. It has phase III evidence, a clear mechanism, FDA approval, more than fifteen years of post-approval safety data, and a defined indication that overlaps meaningfully with one of the UAE's most common metabolic problems. Off-label use for visceral adiposity in the metabolically-at-risk patient sits on a real evidence base, particularly in NAFLD, and is one of the more defensible off-label peptide conversations a UAE physician can have with a well-screened patient.
The same caveats that apply to every peptide apply here. The decision belongs in a clinic, not on a forum. The lab work is non-negotiable. The contraindications are real, and the IGF-1 / cancer-risk conversation is not optional. The drug treats a specific tissue compartment, not weight in general. Patients who arrive expecting a body-recomposition shortcut will leave disappointed. Patients who arrive with documented visceral adiposity and a real metabolic risk profile, and who are willing to pair the protocol with the lifestyle changes that should have come first, often see exactly the response the phase III data predicts.
If you fit the phenotype the article opened with, talk to a licensed physician. Bring your lab work. Ask the questions about indication, evidence, and contraindication that any responsible clinic should be ready to answer. This article is educational, not medical advice for your specific situation. The right starting point is a real consultation.
